Search Results for "migraine"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for migraine. Results 21 to 30 of 67 total matches.

A Fixed-Dose Combination of Meloxicam and Rizatriptan (Symbravo) for Migraine

   
The Medical Letter on Drugs and Therapeutics • Apr 28, 2025  (Issue 1727)
A Fixed-Dose Combination of Meloxicam and Rizatriptan (Symbravo) for Migraine ...
The FDA has approved Symbravo (Axsome), an oral fixed-dose combination of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam and the 5-HT1B/1D receptor agonist (triptan) rizatriptan (Maxalt, and generics), for acute treatment of migraine with or without aura in adults. It is the second combination of an NSAID and a triptan to be approved for migraine treatment. An oral fixed-dose combination of sumatriptan and naproxen (Treximet, and generics) is approved for use in patients ≥12 years old.
Med Lett Drugs Ther. 2025 Apr 28;67(1727):68-70   doi:10.58347/tml.2025.1727b |  Show IntroductionHide Introduction

Lasmiditan (Reyvow) and Ubrogepant (Ubrelvy) for Acute Treatment of Migraine

   
The Medical Letter on Drugs and Therapeutics • Mar 09, 2020  (Issue 1593)
Lasmiditan (Reyvow) and Ubrogepant (Ubrelvy) for Acute Treatment of Migraine ...
Lasmiditan (Reyvow – Lilly), an oral serotonin (5-HT1F) receptor agonist, and ubrogepant (Ubrelvy – Allergan), an oral calcitonin gene-related peptide (CGRP) receptor antagonist, have been approved by the FDA for acute treatment of migraine with or without aura in adults.
Med Lett Drugs Ther. 2020 Mar 9;62(1593):35-9 |  Show IntroductionHide Introduction

Corrections: Eloctate for Hemophilia A & Sumatriptan Patch (Zecuity) for Migraine

   
The Medical Letter on Drugs and Therapeutics • Dec 07, 2015  (Issue 1483)
Corrections: Eloctate for Hemophilia A & Sumatriptan Patch (Zecuity) for Migraine ...
Eloctate for Hemophilia A (Med Lett Drugs Ther 2015; 57:143)In the table on page 144, the indications and half-life listed for Nuwiq were erroneously taken from the European package insert. The table has been revised online to reflect the US prescribing information. The cost for Nuwiq has also been updated.A Sumatriptan Patch (Zecuity) for Migraine (Med Lett Drugs Ther 2015; 57:151)In the introduction on page 151, the triptans were referred to as serotonin (5-HT) receptor antagonists; they are 5-HT1B/1D-receptor agonists.Download complete U.S. English...
Med Lett Drugs Ther. 2015 Dec 7;57(1483):168 |  Show IntroductionHide Introduction

A Transcutaneous Electrical Nerve Stimulation Device (Cefaly) for Migraine Prevention

   
The Medical Letter on Drugs and Therapeutics • Aug 18, 2014  (Issue 1449)
A Transcutaneous Electrical Nerve Stimulation Device (Cefaly) for Migraine Prevention ...
The FDA has approved the use of a transcutaneous electrical nerve stimulation device (Cefaly – Cefaly Technology) for prevention of episodic migraine in patients ≥18 years old. The first device to be approved in the US for migraine prevention, it is available in Canada and Europe for treatment and prevention of migraines. A transcranial magnetic stimulation device (SpringTMS - eNeura Therapeutics) recently approved by the FDA for treatment of migraine preceded by aura will be reviewed in a future issue.
Med Lett Drugs Ther. 2014 Aug 18;56(1449):78 |  Show IntroductionHide Introduction

Comparison Table: Some Drugs for Migraine Prevention in Adults (online only)

   
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023  (Issue 1678)
Comparison Table: Some Drugs for Migraine Prevention in Adults (online only) ...
View the Comparison Table: Some Drugs for Migraine Prevention in Adults
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e100-2   doi:10.58347/tml.2023.1678c |  Show IntroductionHide Introduction

In Brief: Warning Against Use of Valproate for Migraine Prevention During Pregnancy

   
The Medical Letter on Drugs and Therapeutics • Jun 10, 2013  (Issue 1418)
In Brief: Warning Against Use of Valproate for Migraine Prevention During Pregnancy ...
The FDA is advising health care professionals not to prescribe valproate sodium (Depacon), valproic acid (Depakene, Stavzor, and generics) or divalproex sodium (Depakote, Depakote ER, and generics) for migraine prevention in pregnant women because a recently published study showed that IQ scores are decreased in children of mothers who took these drugs during pregnancy. The FDA recommends avoiding valproate altogether, if possible, in women of childbearing age.1VALPROATE — Valproic acid and divalproex sodium dissociate to valproate in the GI tract. Valproate is considered the drug of choice...
Med Lett Drugs Ther. 2013 Jun 10;55(1418):45 |  Show IntroductionHide Introduction

In Brief: Hypertension with Erenumab (Aimovig)

   
The Medical Letter on Drugs and Therapeutics • Apr 05, 2021  (Issue 1621)
in 2018 for preventive treatment of migraine in adults.1 Now the FDA has added a new warning to its ...
The once-monthly, subcutaneously injected calcitonin gene-related peptide (CGRP) receptor antagonist erenumab-aooe (Aimovig) was approved by the FDA in 2018 for preventive treatment of migraine in adults. Now the FDA has added a new warning to its labeling about a risk of new-onset hypertension and worsening of preexisting hypertension associated with use of the drug. CGRP is a potent microvascular vasodilator; blocking or deleting it has produced hypertensive effects in animals.
Med Lett Drugs Ther. 2021 Apr 5;63(1621):56 |  Show IntroductionHide Introduction

Onzetra Xsail - Sumatriptan Nasal Powder

   
The Medical Letter on Drugs and Therapeutics • Jul 18, 2016  (Issue 1499)
of migraine in adults. Nasal spray formulations of sumatriptan (Imitrex) and zolmitriptan (Zomig ...
The FDA has approved Onzetra Xsail (Avanir), a nasal powder formulation of sumatriptan, for acute treatment of migraine in adults. Nasal spray formulations of sumatriptan (Imitrex) and zolmitriptan (Zomig) have been available for many years.
Med Lett Drugs Ther. 2016 Jul 18;58(1499):92-3 |  Show IntroductionHide Introduction

In Brief: Erenumab (Aimovig) Hypersensitivity

   
The Medical Letter on Drugs and Therapeutics • Mar 25, 2019  (Issue 1568)
) blocker approved in 2018 for prevention of migraine. The new label contains a warning about ...
The FDA has approved changes to the labeling of erenumab-aooe (Aimovig)1, a once-monthly, subcutaneously injected calcitonin gene-related peptide (CGRP) blocker approved in 2018 for prevention of migraine. The new label contains a warning about hypersensitivity reactions, including rash, angioedema, and anaphylaxis, that have been reported with post-marketing use of the drug.According to the label, most of these reactions were not serious and occurred within hours after receiving the drug, but some occurred more than one week after administration. Because these reactions are voluntarily...
Med Lett Drugs Ther. 2019 Mar 25;61(1568):48 |  Show IntroductionHide Introduction

Acupuncture

   
The Medical Letter on Drugs and Therapeutics • May 08, 2006  (Issue 1234)
months later. 13 Headache – A randomized study in 401 patients with chronic headache (mainly migraine ...
Acupuncture is the practice of inserting fine needles for therapeutic purposes into points on the skin known as acupoints. In traditional Chinese medicine theory, these points arefound along channels that conduct "qi" (pronounced "chee"), or energy. In addition to insertion of needles, acupoints can be stimulated by heat, electrical current or just pressure.
Med Lett Drugs Ther. 2006 May 8;48(1234):38-9 |  Show IntroductionHide Introduction